LL-37 is categorized as Antimicrobial peptide; its regulatory category in this atlas is Research-use-only or no-known-approval compound.
AnimalPEPTIDE DOSSIER
LL-37
LL-37 is classified as Antimicrobial peptide. This profile separates what is known from source-linked evidence, what remains uncertain, safety considerations, and the US regulatory context.
Cathelicidin antimicrobial peptideResearch-use-only caution
Executive Summary
What is it?
LL-37 is a profile in the atlas because people search for it as a peptide, peptide medicine, peptide-like hormone, supplement ingredient, cosmetic peptide, or nearby comparison item. The key question is not just what it is called, but whether a specific product has reliable evidence, clear safety information, and a verified regulatory pathway.
What is it used or studied for?
LL-37 is commonly searched in connection with immune modulation research, antimicrobial research. Some uses may be approved for specific products, while others may only be studied, speculative, cosmetic, supplement-related, or unsupported.
How it interacts with the body
In simple terms, LL-37 is discussed through Cathelicidin peptide involved in innate immune signaling and antimicrobial defense. That means the profile focuses on the body signal, receptor, or pathway it is believed or known to affect, while separating proven labeled uses from research-only claims.
What we know
- - LL-37 is categorized as Antimicrobial peptide.
- - LL-37 currently has evidence grade D in this atlas.
- - Regulatory category: Research-use-only or no-known-approval compound.
What remains uncertain
- - Product-specific legality, quality, and labeling can vary by jurisdiction and supplier.
- - Long-term safety and real-world adverse-event patterns may be incomplete outside approved product contexts.
- - Claims not tied to FDA labeling or human trials should be treated cautiously.
Non-technical takeaway
LL-37 should be read through three filters: what the evidence says, what the regulatory status actually means, and what safety uncertainties remain.
People usually search LL-37 to understand potential uses, how it works in the body, whether it is approved, and what safety concerns or evidence gaps matter.
Key safety considerations
Safety context for LL-37 should be interpreted through product-specific labels or the limits of available research. Non-approved products should not be treated as safe for human use.
Chemical and Scientific Profile
- Peptide type
- Antimicrobial peptide
- Sequence
- Unknown
- Formula
- Unknown
- Molecular weight
- Unknown
- CAS number
- Unknown
- PubChem CID
- 16198951
- Targets
- Unknown
- Routes studied
- not fully characterized
Molecular visualization placeholder
Mechanism of Action
Explain like I’m new
LL-37 is discussed through the pathway: Cathelicidin peptide involved in innate immune signaling and antimicrobial defense. The plain-language interpretation should stay anchored to verified evidence and labeled uses.
Advanced scientific view
Advanced view: Cathelicidin peptide involved in innate immune signaling and antimicrobial defense. Receptor/pathway details require claim-level citations before being treated as clinically meaningful.
Cathelicidin peptide involved in innate immune signaling and antimicrobial defense
Benefits and Claims
Promising
Preclinical Only
LL-37 should be interpreted through source-linked evidence, not marketing claims or protocol claims.
AnimalUnsupported / Safety Claim
LL-37 is not presented here with an approved human self-administration protocol; safety and legal status require caution.
UnsupportedEvidence Dashboard
D
Evidence grade
no adequate FDA-reviewed human efficacy evidence identified in this seed
Human data
mechanistic, in vitro, and preclinical literature dominate popular claims
Animal data
mixed or limited
Citation quality
source search placeholder
Research tracker for LL-37
- Population
- Not yet curated from a specific trial.
- Intervention
- LL-37
- Comparator
- Not yet curated.
- Outcomes
- Research outcomes require manual source review.
- Limitations
- This study card is a seed-level summary and should be replaced by full PICO extraction during editorial review.
- Funding/conflict
- Funding and conflict notes require editorial extraction from the full source.
Dosing and Administration Guardrails
No FDA-approved human dosing protocol is provided here. This profile does not include self-administration, injection, or reconstitution instructions.
This site does not provide personalized protocols, DIY preparation, injection, reconstitution, or self-administration instructions.
Safety Section
Common side effects
- - not well characterized in this seed
Serious warnings
- - unknown long-term safety or product-specific warning gaps
Contraindications
- - not fully characterized; consult product-specific labeling or clinician
Interactions
- - not fully characterized
Regulatory and Sport Status
Research-use-only labeling does not make a compound appropriate for human use, self-experimentation, or injection.
Comparisons
Compare evidence, regulatory status, route, and safety context before treating two compounds as similar.
FAQs
Is LL-37 FDA-approved?
This seed does not verify LL-37 as FDA-approved for general human use. The profile is educational and should not be read as medical advice or a protocol.
What is the main evidence caveat for LL-37?
LL-37 is categorized as Research-use-only or no-known-approval compound. Evidence strength depends on whether a claim comes from FDA labeling, human trials, animal studies, in vitro work, or unsupported marketing.
Does this page provide dosing instructions for LL-37?
No. For non-approved compounds, this site explicitly avoids self-administration, injection, and dosing protocols.